Depo-Provera Settlement Amounts 2026: MDL 3140 Compensation Guide
Depo-Provera settlement amounts in 2026 range from $100,000 to $1.5 million or more, depending on meningioma diagnosis severity, duration of use, and documented economic losses. Depo-Provera lawsuits consolidated in MDL 3140 target Pfizer for alleged failure to warn U.S. patients about the meningioma risk — a warning the FDA finally required in December 2025. If you were diagnosed with an intracranial meningioma after using Depo-Provera, you may qualify for significant compensation. Use our free Depo-Provera settlement calculator for a personalized estimate, or call 1 (855) 664-8713 for a free review. See all settlement amounts by case type →
⚖️ 3,769+ Cases Filed
💰 $100K–$1.5M+ Range
🏥 Meningioma Claims
🆓 Free Case Review
No Win, No Fee
Depo-Provera Settlement Amounts 2026: What to Expect
Depo-Provera settlement amounts have not yet been officially set because MDL 3140 has not reached global resolution. However, based on analogous pharmaceutical mass torts, plaintiff attorneys project Depo-Provera settlement compensation tiers ranging from $100,000 for less severe cases to more than $1.5 million for those with aggressive meningioma requiring surgery, radiation, or causing permanent neurological disability. The individual Depo-Provera settlement value depends on your specific medical record, documented usage history, and injury severity.
Depo-Provera settlement amounts tier breakdown for MDL 3140 — $100K to $1.5M+ based on injury severity
A landmark March 2024 study published in the British Medical Journal demonstrated a 5.6-fold increased risk of intracranial meningioma in women who used Depo-Provera for more than one year — foundational science that strengthens every plaintiff’s causation argument. A subsequent September 2025 study in JAMA Neurology analyzed over 10 million U.S. women and found a 2.43-fold increased meningioma risk — corroborating dose-response relationships consistent with legal causation standards. In December 2025, the FDA formally required Pfizer to add a meningioma warning to the Depo-Provera label.
Latest Depo-Provera MDL 3140 Updates — May 2026
May 2026: 3,769 Cases — Daubert Hearings June 24–26
As of May 2026, MDL 3140 in the Northern District of Florida before Judge M. Casey Rodgers holds 3,769 active Depo-Provera settlement claims. Daubert hearings on causation and general liability experts are scheduled for June 24–26, 2026. Plaintiff attorneys anticipate these rulings will clear the path for bellwether trial scheduling, driving global Depo-Provera settlement negotiations.
March 2026: Pfizer Preemption Motion Fully Briefed
Pfizer’s federal preemption motion — arguing the FDA prevented it from adding a meningioma warning — has been fully briefed following a supplemental round after the December 2025 FDA label change. Legal analysts believe the FDA’s reversal severely weakens Pfizer’s preemption argument, which if lost would open all 3,769 cases to trial and increase Depo-Provera settlement amounts significantly.
December 2025: FDA Requires Meningioma Warning on U.S. Label
The FDA formally required updated labeling for Depo-Provera CI and Depo-SubQ Provera 104, explicitly warning of meningioma risk after repeated use. This regulatory action significantly strengthens failure-to-warn arguments and could push Depo-Provera settlement amounts above initial projections.
December 7, 2026: First Bellwether Trial — Toney v. Pfizer
The first bellwether trial in MDL 3140 is scheduled for December 7, 2026. Bellwether verdicts set the financial benchmark that anchors global settlement negotiations. Filing early places your claim in the strongest position ahead of these outcomes.
Depo-Provera Settlement Amounts: Tier Breakdown
- Aggressive or recurrent meningioma
- Surgery + radiation required
- Permanent neurological deficit
- Cognitive impairment or disability
- 10+ years Depo-Provera use
- Single surgery, tumor controlled
- Partial neurological deficit
- Extended recovery period
- Significant documented wage loss
- 5–10 years use
- Watch-and-wait diagnosis
- Smaller, non-symptomatic tumor
- Minimal treatment
- Limited economic impact
- 1–5 years use
Who Qualifies for Depo-Provera Settlement Amounts?
To qualify for Depo-Provera settlement compensation in MDL 3140, you generally must meet the following criteria. Visit our full Depo-Provera lawsuit eligibility guide for complete details.
- You received Depo-Provera (medroxyprogesterone acetate) injections for at least 12 months
- You were diagnosed with an intracranial meningioma brain tumor
- Your diagnosis occurred after or during your period of Depo-Provera use
- You have medical records documenting both the injection history and tumor diagnosis
- Your claim falls within the applicable statute of limitations for your state (typically 2–4 years from diagnosis)
⏰ Statute of Limitations Warning
Deadlines vary by state — typically 2–4 years from diagnosis or discovery of the Depo-Provera connection. Call 1 (855) 664-8713 immediately to confirm your filing window has not closed.
⚡ Find Out If You Qualify for Depo-Provera Settlement Compensation
Free, confidential case review — no obligation, no upfront fees. Our mass tort attorneys respond within 24 hours.
By submitting, you consent to being contacted about your Depo-Provera meningioma claim. No attorney-client relationship is formed until a signed fee agreement is executed. No Win, No Fee.
⚖️ How to File a Depo-Provera Claim: Step-by-Step
Key Factors That Affect Depo-Provera Settlement Amounts
Duration of Use
Longer Depo-Provera use (5+ years) correlates with higher tumor risk and stronger causation evidence, increasing your Depo-Provera settlement value. The JAMA 2025 study found highest risk at 4+ years.
Tumor Size & Grade
WHO Grade II or III meningiomas command the highest Depo-Provera settlement amounts in the tier system due to greater injury severity, recurrence risk, and treatment intensity.
Treatment Intensity
Craniotomy surgery, stereotactic radiosurgery, or combined treatment protocols significantly increase documented damages and Depo-Provera settlement compensation.
Neurological Impact
Vision loss, hearing loss, cognitive impairment, or motor deficits constitute severe injury categories that support Tier 1 Depo-Provera settlement amounts.
Economic Loss
Lost wages, reduced earning capacity, and future medical care costs add quantifiable damages to your Depo-Provera settlement claim value.
Documentation Quality
Complete injection records paired with continuous imaging and treatment records significantly strengthen your Depo-Provera settlement position in MDL 3140.
💬 Find Out What Your Depo-Provera Settlement May Be Worth
Our network of mass tort attorneys has evaluated thousands of Depo-Provera settlement claims. Get a free, no-obligation case review in minutes.
📞 Call 1 (855) 664-8713 — Free Consultation
No Win, No Fee · Confidential · Available 24/7
Depo-Provera Settlement Amounts vs. Comparable Mass Tort Verdicts
The Depo-Provera MDL follows patterns seen in comparable pharmaceutical mass torts. Roundup litigation yielded settlements averaging $160,000 per claim in Monsanto’s $10.9 billion global resolution. Talcum powder ovarian cancer verdicts reached billions before J&J’s settlement program. While Depo-Provera settlement amounts are still emerging, a well-documented case with serious neurological injury could command substantial individual compensation. Compare all mass tort settlement amounts →
State-by-State Considerations for Depo-Provera Settlement Amounts
Your state’s statute of limitations affects your Depo-Provera settlement claim filing deadline. Most states allow 2–4 years from the date of meningioma diagnosis. States including California, New York, and Illinois extend your filing window using the discovery rule — meaning the clock starts when you discovered (or should have discovered) the connection to Depo-Provera. Contact an attorney immediately to determine your specific deadline for Depo-Provera settlement eligibility.
📚 Related Depo-Provera Resources
Frequently Asked Questions: Depo-Provera Settlement Amounts 2026
How much are Depo-Provera settlement amounts in 2026?
Depo-Provera settlement amounts in 2026 are projected between $100,000 and $1.5 million or more per qualifying plaintiff. No official global settlement amount has been set — MDL 3140 has not reached resolution. The first bellwether trial (Toney v. Pfizer, December 7, 2026) will anchor the final global Depo-Provera settlement range. Use our free Depo-Provera settlement calculator for a personalized estimate.
Who qualifies for a Depo-Provera settlement?
Qualifying plaintiffs generally must have used Depo-Provera for at least 12 months and received a subsequent diagnosis of intracranial meningioma. Medical records documenting both the injection history and tumor diagnosis are essential to establish your Depo-Provera settlement claim. Visit our full eligibility guide for detailed criteria.
How long will Depo-Provera settlement payments take?
Based on comparable pharmaceutical MDLs, individual claimants typically begin receiving Depo-Provera settlement payments 2–3 years after filing. The first bellwether trial is December 2026 — global settlement negotiations typically follow 6–12 months after bellwether outcomes, putting potential resolution in the 2027–2028 range.
Is there a free Depo-Provera settlement amount calculator?
Yes. TortAdvisor provides a free Depo-Provera settlement calculator that estimates your claim value based on injury tier, treatment history, and duration of use — using the same methodology plaintiff attorneys use for MDL 3140 case evaluation.
What does a Depo-Provera attorney cost?
Mass tort attorneys handling Depo-Provera settlement claims work on contingency — you pay zero attorney fees unless you receive a settlement or verdict. The standard contingency fee in MDL pharmaceutical cases is typically 33–40% of the gross recovery. There are no upfront costs of any kind.
Is Pfizer settling Depo-Provera lawsuits?
As of May 2026, Pfizer has not announced a global Depo-Provera settlement. However, plaintiff attorneys expect settlement negotiations to accelerate significantly following the December 2026 bellwether trial results in MDL 3140. The December 2025 FDA label change requiring a meningioma warning has significantly strengthened plaintiffs’ position.
Did the FDA warn about Depo-Provera and meningioma?
Yes. In December 2025, the FDA approved a label change requiring Pfizer to warn that cases of meningioma have been reported following repeated use of medroxyprogesterone acetate, primarily with long-term use. The updated FDA prescribing label applies to both Depo-Provera CI and Depo-SubQ Provera 104, and directly undermines Pfizer’s preemption defense.
Sources & Citations
- Roland N, et al. “Use of progestogens and risk of intracranial meningioma.” BMJ 2024;384:e078078 — 5.6x meningioma risk study
- Xiao T, et al. “Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US.” JAMA Neurology 2025 — 2.43x risk, 10M+ women
- MDL 3140 official court page — Northern District of Florida, Judge M. Casey Rodgers
- MDL No. 3140 federal docket — CourtListener (free public access)
- FDA-approved Depo-Provera prescribing information — December 2025 (meningioma warning)
- PubMed: peer-reviewed medroxyprogesterone and meningioma research index
